ATLANTA, GA – – (ACCESSWIRE – December 8, 2022) – – Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). The lawsuit alleges NeoGenomics made materially false and misleading statements, and/or failed to disclose, material adverse facts including: (i) contrary to its claims, the Company was not a “one-stop shop” for cancer testing because it did not offer the most technologically advanced next generation sequencing tests, causing a significant decrease in revenue as current and prospective customers went elsewhere for their testing needs; (ii) the Company’s costs were not fixed because NeoGenomics needed to hire additional employees to process more complex customized testing demanded by customers utilizing the Company’s outdated portfolio of tests, leading to operational challenges, decreased lab efficiency, and increased testing turnaround times; and (iii) NeoGenomics violated federal healthcare laws and regulations related to fraud, waste, and abuse.
If you bought shares of NeoGenomics between February 27, 2020 and April 26, 2022, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/neogenomics/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is February 6, 2023.
Lead Plaintiff Deadline Has Passed
February 6, 2023